Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
United States
100%
Clinical Benefit
100%
Stroke Patients
100%
Economic Benefits
100%
Cryptogenic Stroke
100%
Patent Foramen Ovale
100%
Recurrent Stroke
27%
Diagnostic Test
18%
Markov Model
18%
Cost Savings
18%
Quality-adjusted Life Years
18%
Incremental Cost-effectiveness Ratio
18%
Decision Tree
18%
Lifesaving
9%
Health Status
9%
Payers
9%
Stroke Risk
9%
Ischemic Stroke
9%
Current Diagnostics
9%
Cost-effectiveness
9%
Sensitivity Analysis
9%
Recurrent Ischemic Stroke
9%
Health Outcomes
9%
Diagnostic Guidelines
9%
Accurate Determination
9%
Cost-effectiveness Analysis
9%
Simulated Patient
9%
Secondary Stroke Prevention
9%
Payer Perspective
9%
Economic Impact
9%
Underuse
9%
Diagnostic Practices
9%
Diagnostic Pathway
9%
Hybrid Model
9%
Health Economics
9%
Willingness-to-pay Threshold
9%
Patent Foramen Ovale Closure
9%
Improving Health Outcomes
9%
Testing Rates
9%
QALYs Gained
9%
Stroke Etiology
9%
Economic Position
9%
Nursing and Health Professions
Cerebrovascular Accident
100%
Patent Foramen Ovale
100%
Quality Adjusted Life Year
25%
Cost Control
16%
Practice Guideline
16%
Brain Ischemia
16%
Cost Effectiveness Analysis
16%
Incremental Cost-Effectiveness Ratio
16%
Health Outcomes
16%
Decision Tree
16%
Health Status
8%
Transient Ischemic Attack
8%
Medicine and Dentistry
Apoplexy
100%
Patent Foramen Ovale
100%
Cost-Effectiveness Analysis
33%
Quality Adjusted Life Year
25%
Health Care Cost
16%
Diagnostic Testing
16%
Brain Ischemia
16%
Health Outcomes
16%
Health Status
8%
Lifespan
8%
Transient Ischemic Attack
8%
Psychology
Stroke Patient
100%
Markov Model
100%
Time Horizon
50%